

FOR PUBLIC RELEASE

NZX Limited
Wellington

Wednesday, 12 October 2022

Results of Rua Bioscience Limited's 2022 Annual Shareholders' Meeting

At Rua Bioscience Limited's hybrid Rua Bioscience Annual Shareholders' Meeting (held online and in Gisborne today) shareholders were asked to vote on four ordinary resolutions, which were supported by the Board.

As required by NZX Listing Rule 6.1, all voting was conducted by a poll.

The resolutions passed by the shareholders were:

- Resolution One: That the Board be authorised to fix the auditor's remuneration.
- Resolution Two: That Trevor Burt be re-elected as a director of Rua.
- Resolution Three: That Brett Gamble be re-elected as a director of Rua.
- Resolution Four: That Teresa Ciprian be re-elected as a director of Rua.

Detail of the total number of votes cast in person or by a proxy are as follows:

Resolution	For	Against	Abstain
That the Board be authorised to fix the auditor's remuneration.	21,767,683 99.54%	101,337 0.46%	115,047
The Trevor Burt, who retires and is eligible for re-election, be elected as a director of Rua.	21,628,631 99.43%	123,629 0.57%	231,807
The Brett Gamble, who retires and is eligible for re-election, be elected and a director of Rua.	21,596,650 99.28%	155,980 0.72%	231,437
That Teresa Ciprian (appointed by the board as a director from 1 August 2022), who retires and is eligible for re-election, be elected as a director of Rua.	21,707,089 99.64%	79,227 0.36%	197,751

Director Independence

As required by the NZX Listing Rules, the Board of Rua Bioscience has determined that the following Directors are Independent Directors:

- Trevor Burt
- Teresa Ciprian

Authority for this Announcement	
Name of the person authorised to make this announcement	Hamish White
Contact person for this announcement	Chief Financial Officer & Company Secretary
Contact phone number	+64 (21) 050 5795
Contact email address	Hamish.white@ruabio.com
Date of release through MAP	12/10/2022

Ends

For more information, please visit www.ruabio.com or contact:

Media

Kerry Donovan
Communications Manager
+64 (21) 128 7689
kerry.donovan@ruabio.com

Investors

Hamish White
Chief Financial Officer
+64 (21) 050 5795
Hamish.white@ruabio.com

About Rua Bioscience

Rua Bioscience is a New Zealand pharmaceutical company aiming to produce cannabinoid derived medicines for both export and local markets. Rua has been an early mover in the sector and was the first private company in New Zealand to receive a licence to cultivate Cannabis for research purposes. Founded in 2017 in Ruatorea as a subsidiary of charitable company Hikurangi Enterprises Limited, Rua is underpinned by its mission to heal the people and heal the land. It is committed to New Zealand's Te Tairāwhiti (East Coast) region and its local community. The Company has completed facilities for cultivation and manufacturing and is currently going through the GMP certification process. www.ruabio.com